SPA
ZVRA icon

Sherbrooke Park Advisers’s Zevra Therapeutics ZVRA Stock Holding History

Sherbrooke Park Advisers’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,217
Closed -$108K – 751
2025
Q2 		$108K Buy
+12,217
New +$99.1K 0.05% 452

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Sherbrooke Park Advisers's ZVRA Position: Q3 2025 in Review

Sherbrooke Park Advisers sold out of Zevra Therapeutics (ZVRA) in Q3 2025, closing a stake of 12,217 shares — an estimated $108K sold.

Sherbrooke Park Advisers first reported a position in ZVRA in Q2 2025 and held it in 1 quarter. The position peaked at $108K in Q2 2025. 166 funds tracked by Wall St. Rank hold ZVRA as of Q3 2025.

  • Sherbrooke Park Advisers reported no remaining Zevra Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 12,217 Zevra Therapeutics shares in Q3 2025, an estimated $108K.
  • Sherbrooke Park Advisers first reported a position in Zevra Therapeutics in Q2 2025 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Zevra Therapeutics position peaked at $108K in Q2 2025.
  • 166 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.